BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15456955)

  • 1. Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
    Avilés A; Nambo MJ; Neri N; Talavera A; Castañeda C; Murillo E; Cleto S; Huerta-Guzmán J
    Med Oncol; 2004; 21(3):269-72. PubMed ID: 15456955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
    Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
    Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
    Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
    Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.
    Avilés A; Cleto S; Huerta-Guzmán J; Neri N
    Eur J Haematol; 2001 Feb; 66(2):94-9. PubMed ID: 11168516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
    Avilés A; Calva A; Díaz-Maqueo JC; Talavera A; Huerta-Guzmán J; Vásquez E
    Leuk Lymphoma; 1997 Apr; 25(3-4):319-25. PubMed ID: 9168442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE.
    Raderer M; Valencak J; Osterreicher C; Drach J; Hejna M; Kornek G; Scheithauer W; Brodowicz T; Chott A; Dragosics B
    Cancer; 2000 May; 88(9):1979-85. PubMed ID: 10813708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma.
    Bower M; Brock C; Gulliford T; O'Reilly SM; Smith DB; Newlands ES
    Cancer Chemother Pharmacol; 1996; 38(1):106-9. PubMed ID: 8603443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
    Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
    J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen.
    Avilés A; Nambo MJ; Halabe J
    Ann Hematol; 1999 Jan; 78(1):9-12. PubMed ID: 10037262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
    Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
    Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Dose Chemotherapy in the Treatment of Poor Prognosis Malignant Lymphoma.
    Avilés A; Talavera A; Díaz-Maqueo JC; Cleto S; Díaz NR; García EL
    Hematology; 1998; 3(3):229-33. PubMed ID: 27416532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
    Fierro MT; Doveil GC; Quaglino P; Savoia P; Verrone A; Bernengo MG
    Dermatology; 1997; 194(3):268-72. PubMed ID: 9187846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
    Avilés A; Neri N; Huerta-Guzmán J; Pérez F; Sotelo L
    Leuk Lymphoma; 2004 Nov; 45(11):2247-51. PubMed ID: 15512813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
    Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
    Avilés A; Nambo MJ; Neri N; Cleto S; Castañeda C; Huerta-Guzmàn J; Murillo E; Contreras M; Talavera A; González M
    Med Oncol; 2007; 24(1):85-9. PubMed ID: 17673816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast lymphoma.
    Avilés A
    Ann Oncol; 2008 Jul; 19(7):1360. PubMed ID: 18579558
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.